137 related articles for article (PubMed ID: 29041009)
1. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.
Kline JB; Kennedy RP; Albone E; Chao Q; Fernando S; McDonough JM; Rybinski K; Wang W; Somers EB; Schweizer C; Grasso L; Nicolaides NC
Oncotarget; 2017 Aug; 8(32):52045-52060. PubMed ID: 28881712
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
Hurvitz SA; Betting DJ; Stern HM; Quinaux E; Stinson J; Seshagiri S; Zhao Y; Buyse M; Mackey J; Driga A; Damaraju S; Sliwkowski MX; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Pienkowski T; Eiermann W; Martin M; Bee V; Marathe O; Slamon DJ; Timmerman JM
Clin Cancer Res; 2012 Jun; 18(12):3478-86. PubMed ID: 22504044
[TBL] [Abstract][Full Text] [Related]
4. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
[TBL] [Abstract][Full Text] [Related]
5. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Han SW; Jeon YK; Oh DY; Han W; Kim TY; Park IA; Noh DY; Bang YJ
Oncology; 2012; 83(4):218-27. PubMed ID: 22906996
[TBL] [Abstract][Full Text] [Related]
6. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.
Paul P; Pedini P; Lyonnet L; Di Cristofaro J; Loundou A; Pelardy M; Basire A; Dignat-George F; Chiaroni J; Thomas P; Reynaud-Gaubert M; Picard C
Front Immunol; 2019; 10():1208. PubMed ID: 31249568
[TBL] [Abstract][Full Text] [Related]
7. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
8. Effect of FCGR2A and FCGR3A variants on CLL outcome.
Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
[TBL] [Abstract][Full Text] [Related]
9. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population.
Sadki K; Lamsyah H; Rueda B; Akil E; Sadak A; Martin J; El Aouad R
J Genet Genomics; 2010 Apr; 37(4):257-64. PubMed ID: 20439102
[TBL] [Abstract][Full Text] [Related]
10. FC gamma receptor polymorphisms in patients with immune thrombocytopenia.
Pavkovic M; Petlichkovski A; Karanfilski O; Cevreska L; Stojanovic A
Hematology; 2018 Apr; 23(3):163-168. PubMed ID: 28942727
[TBL] [Abstract][Full Text] [Related]
11. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
[TBL] [Abstract][Full Text] [Related]
12. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
[TBL] [Abstract][Full Text] [Related]
13. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
[TBL] [Abstract][Full Text] [Related]
14. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
15. NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation.
Moraru M; Black LE; Muntasell A; Portero F; López-Botet M; Reyburn HT; Pandey JP; Vilches C
J Immunol; 2015 Aug; 195(4):1676-84. PubMed ID: 26179905
[TBL] [Abstract][Full Text] [Related]
16. Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.
O'Shannessy DJ; Bendas K; Schweizer C; Wang W; Albone E; Somers EB; Weil S; Meredith RK; Wustner J; Grasso L; Landers M; Nicolaides NC
Genomics; 2017 Jul; 109(3-4):251-257. PubMed ID: 28450240
[TBL] [Abstract][Full Text] [Related]
17. Simple genotyping of functional polymorphisms of the human immunoglobulin G receptors CD16A and CD32A: a reference cell panel.
Vilches C; Castaño J; Muñoz P; Peñalver J
Tissue Antigens; 2008 Mar; 71(3):242-6. PubMed ID: 18179643
[TBL] [Abstract][Full Text] [Related]
18. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
20. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
